Photo of Anita K. Wagner,  PharmD, MPH, DrPH

Anita K. Wagner, PharmD, MPH, DrPH

Harvard Medical School

Harvard Medical School
Phone: (617) 867-4956
Fax: (617) 867-4276

Anita K. Wagner, PharmD, MPH, DrPH

Harvard Medical School


  • Associate Professor, Population Medicine, Harvard Medical School
  • Co-Director, DPM Center for Cancer Policy and Program Evaluation, Department of Population Medicine (DPM), Harvard Medical School
  • Co-Director, HMS Fellowship in Health Policy and Insurance Research, Department of Population Medicine (DPM), Harvard Medical School


Research Abstract

The Center for Cancer Policy and Program Evaluation (CarPE) within the Department of Population Medicine (DPM) serves as a catalyst for rigorous and impactful policy research across the cancer care continuum by faculty in the DPM and our external collaborators. Our mission is to generate sound evidence to inform policies and programs, for use by stakeholders in the United States and elsewhere. We leverage the diverse research expertise of DPM faculty, effectively use and expand DPM’s large population-based electronic data resources, and actively collaborate with delivery system and payer partners of the DPM.

Within CarPE, Dr. Wagner conducts empirical research to generate evidence for answering ethically challenging health system questions related to new, highly-priced cancer therapeutics. Her work, frequently in large databases, evaluates impacts of insurance and other policy changes on the availability, access, affordability, and use of new cancer medicines, in the United States, China, and elsewhere.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Shahzad M, Naci H, Wagner AK. Estimated Medicare Spending on Cancer Drug Indications With a Confirmed Lack of Clinical Benefit After US Food and Drug Administration Accelerated Approval. JAMA Intern Med 2021. PubMed
  • Fu M, Naci H, Booth CM, Gyawali B, Cosgrove A, Toh S, Xu Z, Guan X, Ross-Degnan D, Wagner AK. Real-world Use of and Spending on New Oral Targeted Cancer Drugs in the US, 2011-2018. JAMA Intern Med 2021. PubMed
  • Naci H, Guan X, Woloshin S, Xu Z, Wagner AK. Communication of Survival Data in US Food and Drug Administration-Approved Labeling of Cancer Drugs. JAMA Intern Med 2021. PubMed
  • Hughes TM, Empringham B, Wagner AK, Ward ZJ, Yeh J, Gupta S, Frazier AL, Denburg AE. Forecasting essential childhood cancer drug need: An innovative model-based approach. Cancer 2021. PubMed
  • Ferrario A, Xu X, Zhang F, Ross-Degnan D, Wharam JF, Wagner AK. Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States. JCO Oncol Pract 2021; 17:e194-e203. PubMed
  • Leopold C, Haffajee RL, Lu CY, Wagner AK. The Complex Cancer Care Coverage Environment - What is the Role of Legislation? A Case Study from Massachusetts. J Law Med Ethics 2020; 48:538-551. PubMed
  • Leopold C, Araujo-Lane C, Rosenberg C, Gilkey M, Wagner AK. Out-of-Pocket Cancer Care Costs and Value Frameworks: A Case Study in a Community Oncology Practice with a Financial Navigator Program. Pharmacoecon Open 2019. PubMed
  • J. Frank Wharam, Fang Zhang, Christine Y. Lu, Anita K. Wagner, Larissa Nekhlyudov, Craig C. Earle, Stephen B. Soumerai, and Dennis Ross-Degnan. Breast Cancer Diagnosis and Treatment After High- Deductible Insurance Enrollment J Clin Oncol 2018; 36:1121-1127.
Member Summary Video